Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
CTAGE family member 6 (CTAGE6), also known as “protein cTAGE-6” or via its pseudogene annotation CTAGE6P, is a predicted protein-coding gene associated with ER-to-Golgi vesicle transport and protein secretion[2]. Its protein product is predicted to be membrane-associated, located at endoplasmic reticulum exit sites and the ER membrane. There is no evidence that CTAGE6 has been leveraged as a target for therapeutic intervention, nor is it classified under major families such as receptors, enzymes, transporters, or transcription factors. Disease associations (Waisman Syndrome, hereditary keratitis) are found in annotation databases but lack strong mechanistic or clinical support. The gene remains poorly characterized, with limited information on biological roles and no validated drug interactions or functional biomarkers[2].
Not applicable; no drugs targeting CTAGE6 are reported.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on CTAGE family member 6 (CTAGE6).